Technical Analysis for KRON - Kronos Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Historical KRON trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | -1.22% | |
| 50 DMA Support | Bullish | -1.22% | |
| NR7 | Range Contraction | -1.22% | |
| 20 DMA Resistance | Bearish | -1.80% | |
| Crossed Above 50 DMA | Bullish | -1.80% | |
| 180 Bullish Setup | Bullish Swing Setup | -1.80% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.80% | |
| 20 DMA Resistance | Bearish | 1.41% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | 1 day ago | |
| 20 DMA Resistance | 1 day ago | |
| Up 1% | 1 day ago | |
| 50 DMA Support | 1 day ago | |
| 10 DMA Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Sector: Other
Industry: Other
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Novel Cancer Transcription Factors Transcription Factor Cyclin Dependent Kinase Entospletinib Kronos Morpholines
Classification
Sector: Other
Industry: Other
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Novel Cancer Transcription Factors Transcription Factor Cyclin Dependent Kinase Entospletinib Kronos Morpholines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.6 |
| 52 Week Low | 25.5 |
| Average Volume | 220,677 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 31.73 |
| 20-Day Moving Average | 32.43 |
| 10-Day Moving Average | 31.01 |
| Average True Range | 2.48 |
| ADX | 16.15 |
| +DI | 21.79 |
| -DI | 17.41 |
| Chandelier Exit (Long, 3 ATRs ) | 31.53 |
| Chandelier Exit (Short, 3 ATRs ) | 34.96 |
| Upper Bollinger Band | 37.07 |
| Lower Bollinger Band | 27.79 |
| Percent B (%b) | 0.41 |
| BandWidth | 28.63 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.50 | ||||
| Resistance 3 (R3) | 34.48 | 33.48 | 34.01 | ||
| Resistance 2 (R2) | 33.48 | 32.74 | 33.49 | 33.84 | |
| Resistance 1 (R1) | 32.53 | 32.28 | 33.01 | 32.55 | 33.68 |
| Pivot Point | 31.53 | 31.53 | 31.77 | 31.54 | 31.53 |
| Support 1 (S1) | 30.58 | 30.79 | 31.06 | 30.60 | 29.46 |
| Support 2 (S2) | 29.58 | 30.33 | 29.59 | 29.30 | |
| Support 3 (S3) | 28.63 | 29.58 | 29.13 | ||
| Support 4 (S4) | 28.65 |
